March 1st 2024
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
March 1st 2023
Neal Shore, MD, FACS, US discusses the continued evaluation of darolutamide in patients with non-metastatic castration-resistant prostate cancer.
December 8th 2021
Neal D. Shore, MD, FACS, discusses the rationale for the open-label, randomized phase 2 ENACT trial in prostate cancer.
August 23rd 2021
Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses the clinical utility of piflufolastat F 18 in identifying suspected metastasis or recurrence of prostate cancer.
June 24th 2021
Neal D. Shore, MD, FACS, discusses the design of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.
April 1st 2021
Neal D. Shore, MD, FACS, discusses future research directions with darolutamide for the treatment of patients with prostate cancer.
September 23rd 2020
Neal D. Shore, MD, FACS, discusses the objective of the phase 3 HERO trial in advanced prostate cancer.
August 4th 2020
Neal D. Shore, MD, FACS, discusses challenges with androgen deprivation therapy in recurrent prostate cancer.
July 20th 2020
Neal D. Shore, MD, FACS, discusses the safety and tolerability benefits of darolutamide in men with nonmetastatic castration resistant prostate cancer.
August 7th 2016
Neal Shore, MD, medical director of the Carolina Urologic Research Institute, discusses a retrospective study investigating the relationship between treatment costs and the timing of diagnosis of metastases in prostate cancer.
August 10th 2015
Neal D. Shore, MD, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses preliminary results of the Harris poll, which surveyed how men with advanced prostate cancer communicate with their practitioners.
May 20th 2015
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses the results of the TERRAIN trial.
May 23rd 2014
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses a long-term safety analysis of the COU-AA-302 study, which he presented at the 2014 AUA Annual Meeting.
January 30th 2014
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the androgen receptor inhibitor ODM-201, which is used to treat castration-resistant prostate cancer.
January 27th 2014
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses genomic assays in prostate cancer.
September 19th 2013
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the approval of radium-223 for patients with bone metastases from prostate cancer.
August 26th 2013
Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.
July 24th 2013
Neal D. Shore, MD, FACS, discusses an analysis of degarelix and luteinising hormone-releasing hormone (LHRH) agonists in prostate cancer.
June 20th 2013
Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, gives an overview of the development of immunotherapies for patients with prostate cancer.
June 28th 2012
Neal D. Shore, MD, Managing Partner, Atlantic Urology Clinics, Director, CPI, Carolina Urologic Research Center, discusses enzalutamide, a well tolerated oral therapy.